Drug intelligence / Profile preview

Yinao Jieyu

Development stage: Unknown
Lead developer: Zhongjing Wanxi Pharmaceuticals
Administration: Oral

Overview

Yinao Jieyu is a Traditional Chinese Medicine (TCM) granule formulation developed by Zhongjing Wanxi Pharmaceutical for the treatment of depression, specifically targeting the Kidney Deficiency and Liver Stagnation (肾虚肝郁) syndrome. As a botanical-based therapy, it is designed to regulate emotional states and alleviate depressive symptoms by addressing underlying patterns of disharmony according to TCM principles. The drug has been evaluated in Phase 2 clinical trials in China to establish efficacy and safety data required to support the design of Phase 3 registration trials.

Other names: Yinao Jieyu Keli颐脑解郁颗粒

Targets

NOTCH (Neurogenic locus notch homolog protein 3)GABAA (Gamma-aminobutyric acid receptor)

Beyond the preview

Go deeper on Yinao Jieyu.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yinao Jieyu.

Explore the full profile